Our in vitro and in vivo studies demonstrate that SH003 inhibits VEGF-induced tumor angiogenesis by blocking VEGFR2-mediated signaling, which suggest that metronomic SH003 treatment could be useful for treating cancer. This evidence concerns the gene KDR and neoplasm.